Metabolism of Acetaminophen by Enteric Epithelial Cells Mitigates Hepatocellular Toxicity In Vitro.

Caco-2 HepaRG acetaminophen enterohepatic circulation gut–liver axis paracetamol tight junctions

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
12 Jun 2023
Historique:
received: 14 04 2023
revised: 25 05 2023
accepted: 05 06 2023
medline: 28 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

The gut-liver axis is defined by dietary and environmental communication between the gut, microbiome and the liver with its redox and immune systems, the overactivation of which can lead to hepatic injury. We used media preconditioning to mimic some aspects of the enterohepatic circulation by treating the human Caco-2 intestinal epithelial cell line with 5, 10 and 20 mM paracetamol (N-acetyl-para-aminophenol; APAP) for 24 h, after which cell culture supernatants were transferred to differentiated human hepatic HepaRG cells for a further 24 h. Cell viability was assessed by mitochondrial function and ATP production, while membrane integrity was monitored by cellular-based impedance. Metabolism by Caco-2 cells was determined by liquid chromatography with tandem mass spectrometry. Caco-2 cell viability was not affected by APAP, while cell membrane integrity and tight junctions were maintained and became tighter with increasing APAP concentrations, suggesting a reduction in the permeability of the intestinal epithelium. During 24 h incubation, Caco-2 cells metabolised 64-68% of APAP, leaving 32-36% of intact starting compound to be transferred to HepaRG cells. When cultured with Caco-2-preconditioned medium, HepaRG cells also showed no loss of cell viability or membrane integrity, completely in contrast to direct treatment with APAP, which resulted in a rapid loss of cell viability and membrane integrity and, ultimately, cell death. Thus, the pre-metabolism of APAP could mitigate previously observed hepatotoxicity to hepatic tight junctions caused by direct exposure to APAP. These observations could have important implications for the direct exposure of hepatic parenchyma to APAP, administered via the intravenous route.

Identifiants

pubmed: 37373688
pii: jcm12123995
doi: 10.3390/jcm12123995
pmc: PMC10299659
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Front Immunol. 2021 Apr 16;12:660179
pubmed: 33936094
Med Sci (Basel). 2018 Sep 17;6(3):
pubmed: 30227645
J Control Release. 2021 Jul 10;335:247-268
pubmed: 34033859
J Pharm Pharmacol. 1979 Mar;31(3):157-60
pubmed: 34689
Br J Clin Pharmacol. 2013 Mar;75(3):850-60
pubmed: 22845052
Front Bioeng Biotechnol. 2023 Feb 02;11:1049564
pubmed: 36815881
Sci Rep. 2017 Jan 30;7:37541
pubmed: 28134251
Anaesthesia. 2021 Feb;76(2):270-276
pubmed: 32557588
Biochem J. 1993 Mar 15;290 ( Pt 3):759-64
pubmed: 8096130
Biomed Pharmacother. 2019 Mar;111:1408-1416
pubmed: 30841456
Sci Rep. 2015 Dec 03;5:17455
pubmed: 26632255
Cell Physiol Biochem. 2013;32(2):431-47
pubmed: 23988609
J Hepatol. 2004 Oct;41(4):599-605
pubmed: 15464240
Drug Res (Stuttg). 2021 Nov;71(S 01):S8-S10
pubmed: 34788877
J Clin Med. 2019 Dec 24;9(1):
pubmed: 31878354
Dose Response. 2021 Feb 11;19(1):1559325820987943
pubmed: 33628152
J Pharm Pharmacol. 2009 May;61(5):541-58
pubmed: 19405992
J Hepatol. 2020 Mar;72(3):558-577
pubmed: 31622696
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):27-43
pubmed: 11259831
Pak J Pharm Sci. 2019 Mar;32(2 (Supplementary)):751-757
pubmed: 31103967
Biotechnol Bioeng. 2014 Oct;111(10):2027-40
pubmed: 24954399
BMJ. 2015 Jul 10;351:h3705
pubmed: 26163298
Chem Biol Interact. 2019 Feb 1;299:59-76
pubmed: 30496738
Basic Clin Pharmacol Toxicol. 2017 Jan;120(1):30-37
pubmed: 27285124
Nat Rev Immunol. 2009 Nov;9(11):799-809
pubmed: 19855405
J Lab Autom. 2015 Apr;20(2):107-26
pubmed: 25586998
Hepatology. 2007 Apr;45(4):957-67
pubmed: 17393521
Biochim Biophys Acta. 2008 Mar;1778(3):660-9
pubmed: 17854762

Auteurs

Katie Morgan (K)

Hepatology Laboratory, The University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK.

Steven D Morley (SD)

Hepatology Laboratory, The University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK.

Arslan K Raja (AK)

Hepatology Laboratory, The University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK.

Martin Vandeputte (M)

Hepatology Laboratory, The University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK.

Kay Samuel (K)

Scottish Blood Transfusion Service, Jack Copland Centre, 52 Research Avenue North, Edinburgh EH14 4BE, UK.

Martin Waterfall (M)

Flow Cytometry Facility, Ashworth Laboratories, Institute of Immunology & Infection Research, The University of Edinburgh, The Kings Buildings, Edinburgh EH9 3FL, UK.

Natalie Z M Homer (NZM)

Mass Spectrometry Facility, Centre for Cardiovascular Science, Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.

Peter C Hayes (PC)

Hepatology Laboratory, The University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK.

Jonathan A Fallowfield (JA)

Hepatology Laboratory, The University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK.
Institute for Regeneration and Repair, Edinburgh BioQuarter, The University of Edinburgh, 4-5 Little France Drive, Edinburgh EH16 4UU, UK.

John N Plevris (JN)

Hepatology Laboratory, The University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK.

Classifications MeSH